BRIDGEBIO ONCOLOGY THERAPEUT
BBOTNASDAQTrading Snapshot
- Day Range
- $9.20 โ $9.42
- 52-Week Range
- $7.00 โ $14.87
- Volume
- $4.54B
- Avg Volume
- $3.47B
- Shares Outstanding
- 80.1M
- Next Earnings
- Sep 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $69M
- Last Q Revenue
- $17M
- P/E Ratio
- โ
- P/S Ratio
- โ
- EPS (TTM)
- $-2.30
- Dividend Yield
- โ
Why Investors Own BBOT
- โHigh-growth profile โ revenue up -4.0% YoY with expanding US Equity exposure.
- โHealthy economics โ 69% gross margin and 11% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BRIDGEBIO ONCOLOGY THERAPEUT
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kฮฑ, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
